High-dose chemotherapy followed by reinfusion of a high number of CD34+ progenitor cells is frequently associated with development of fever in the postengraftment period

Anand Jillella, Sandra W Helman, J. Larison, M. S. Litaker, Lloyd O Cook

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Twenty-nine patients received high-dose chemotherapy and autologous stem cell transplantation from June 1997 to December 1998. The number of CD34+ cells reinfused was 2.4 x 106 to 69.0 x 106/kg. Twelve patients developed a fever in the immediate postengraftment period. One patient had a documented infection that could account for the fever; a second patient had a rash and biopsy proven acute graft-versus-host disease (GvHD) that responded to steroids. In the other 10 patients (30%) there was no identifiable cause of the fever. One of these patients received 4.2 x 106 CD34+ cells/kg. The other nine received 22.0 x 106 to 69.0 x 106 CD34+ cells/kg. In our series of 29 patients, 9 of the 11 (82%) patients who received > 20 x 106 CD34+ cells/kg developed fever in the postengraftment period. There was a significant association between the number of CD34+ cells (<20 vs. >20 x 106) and occurrence of fever (odds ratio = 76.5; p = 0.00005). Even though they engrafted promptly (7 to 9 days), the fever required evaluation for infection, blood cultures, antibiotic treatment, and observation. This required additional hospitalization of 1 to 7 days. These data suggest that a high number of CD34+ cells is frequently associated with post-engraftment fever and prolongation of the hospital stay. Should there be an upper limit in the number of reinfused CD34+ cells is a question that has to be addressed and possibly studied.

Original languageEnglish (US)
Pages (from-to)849-854
Number of pages6
JournalJournal of Hematotherapy and Stem Cell Research
Volume9
Issue number6
DOIs
StatePublished - Dec 1 2000

Fingerprint

Fever
Stem Cells
Drug Therapy
Cell Count
Stem Cell Transplantation
Graft vs Host Disease
Infection
Exanthema
Length of Stay
Hospitalization
Odds Ratio
Steroids
Observation
Anti-Bacterial Agents
Biopsy

ASJC Scopus subject areas

  • Immunology
  • Hematology

Cite this

High-dose chemotherapy followed by reinfusion of a high number of CD34+ progenitor cells is frequently associated with development of fever in the postengraftment period. / Jillella, Anand; Helman, Sandra W; Larison, J.; Litaker, M. S.; Cook, Lloyd O.

In: Journal of Hematotherapy and Stem Cell Research, Vol. 9, No. 6, 01.12.2000, p. 849-854.

Research output: Contribution to journalArticle

@article{082ea784be294e70a09939f852422b53,
title = "High-dose chemotherapy followed by reinfusion of a high number of CD34+ progenitor cells is frequently associated with development of fever in the postengraftment period",
abstract = "Twenty-nine patients received high-dose chemotherapy and autologous stem cell transplantation from June 1997 to December 1998. The number of CD34+ cells reinfused was 2.4 x 106 to 69.0 x 106/kg. Twelve patients developed a fever in the immediate postengraftment period. One patient had a documented infection that could account for the fever; a second patient had a rash and biopsy proven acute graft-versus-host disease (GvHD) that responded to steroids. In the other 10 patients (30{\%}) there was no identifiable cause of the fever. One of these patients received 4.2 x 106 CD34+ cells/kg. The other nine received 22.0 x 106 to 69.0 x 106 CD34+ cells/kg. In our series of 29 patients, 9 of the 11 (82{\%}) patients who received > 20 x 106 CD34+ cells/kg developed fever in the postengraftment period. There was a significant association between the number of CD34+ cells (<20 vs. >20 x 106) and occurrence of fever (odds ratio = 76.5; p = 0.00005). Even though they engrafted promptly (7 to 9 days), the fever required evaluation for infection, blood cultures, antibiotic treatment, and observation. This required additional hospitalization of 1 to 7 days. These data suggest that a high number of CD34+ cells is frequently associated with post-engraftment fever and prolongation of the hospital stay. Should there be an upper limit in the number of reinfused CD34+ cells is a question that has to be addressed and possibly studied.",
author = "Anand Jillella and Helman, {Sandra W} and J. Larison and Litaker, {M. S.} and Cook, {Lloyd O}",
year = "2000",
month = "12",
day = "1",
doi = "10.1089/152581600750062273",
language = "English (US)",
volume = "9",
pages = "849--854",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - High-dose chemotherapy followed by reinfusion of a high number of CD34+ progenitor cells is frequently associated with development of fever in the postengraftment period

AU - Jillella, Anand

AU - Helman, Sandra W

AU - Larison, J.

AU - Litaker, M. S.

AU - Cook, Lloyd O

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Twenty-nine patients received high-dose chemotherapy and autologous stem cell transplantation from June 1997 to December 1998. The number of CD34+ cells reinfused was 2.4 x 106 to 69.0 x 106/kg. Twelve patients developed a fever in the immediate postengraftment period. One patient had a documented infection that could account for the fever; a second patient had a rash and biopsy proven acute graft-versus-host disease (GvHD) that responded to steroids. In the other 10 patients (30%) there was no identifiable cause of the fever. One of these patients received 4.2 x 106 CD34+ cells/kg. The other nine received 22.0 x 106 to 69.0 x 106 CD34+ cells/kg. In our series of 29 patients, 9 of the 11 (82%) patients who received > 20 x 106 CD34+ cells/kg developed fever in the postengraftment period. There was a significant association between the number of CD34+ cells (<20 vs. >20 x 106) and occurrence of fever (odds ratio = 76.5; p = 0.00005). Even though they engrafted promptly (7 to 9 days), the fever required evaluation for infection, blood cultures, antibiotic treatment, and observation. This required additional hospitalization of 1 to 7 days. These data suggest that a high number of CD34+ cells is frequently associated with post-engraftment fever and prolongation of the hospital stay. Should there be an upper limit in the number of reinfused CD34+ cells is a question that has to be addressed and possibly studied.

AB - Twenty-nine patients received high-dose chemotherapy and autologous stem cell transplantation from June 1997 to December 1998. The number of CD34+ cells reinfused was 2.4 x 106 to 69.0 x 106/kg. Twelve patients developed a fever in the immediate postengraftment period. One patient had a documented infection that could account for the fever; a second patient had a rash and biopsy proven acute graft-versus-host disease (GvHD) that responded to steroids. In the other 10 patients (30%) there was no identifiable cause of the fever. One of these patients received 4.2 x 106 CD34+ cells/kg. The other nine received 22.0 x 106 to 69.0 x 106 CD34+ cells/kg. In our series of 29 patients, 9 of the 11 (82%) patients who received > 20 x 106 CD34+ cells/kg developed fever in the postengraftment period. There was a significant association between the number of CD34+ cells (<20 vs. >20 x 106) and occurrence of fever (odds ratio = 76.5; p = 0.00005). Even though they engrafted promptly (7 to 9 days), the fever required evaluation for infection, blood cultures, antibiotic treatment, and observation. This required additional hospitalization of 1 to 7 days. These data suggest that a high number of CD34+ cells is frequently associated with post-engraftment fever and prolongation of the hospital stay. Should there be an upper limit in the number of reinfused CD34+ cells is a question that has to be addressed and possibly studied.

UR - http://www.scopus.com/inward/record.url?scp=0034487284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034487284&partnerID=8YFLogxK

U2 - 10.1089/152581600750062273

DO - 10.1089/152581600750062273

M3 - Article

C2 - 11177596

AN - SCOPUS:0034487284

VL - 9

SP - 849

EP - 854

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 6

ER -